Levels of CEA and CA19-9 significantly differed between cohorts, with the highest levels seen in CCA, followed by HCC and with the lowest levels seen in benign liver diseases (p < 0.05). This evidence concerns the gene CEACAM5 and cholangiocarcinoma.